EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Nanomedicine-Enabled in vivo CAR-Macrophage Engineering: Human Evidence, Translational Bottlenecks, and a Validation Framework

Haodong He iD, Jianxuan Sun, Jingyu Xu, Maimaiti Abudureyimu, Yuxuan Yang, Yifan Huang, Zhihua Wang iD, Qidong Xia iD

International Journal of Nanomedicine · 2026-11 · Volume 21 · 1-30

DOI: 10.2147/ijn.s653639 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Nanomedicine, 2026-11. Verfasst von Haodong He und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department and Institute of Urology, Hubei Provincial Clinical Research Center for Minimally Invasive Treatment of Urology, Tongji Hospital, Tongji M…. Hauptthemen laut MEDLINE: Nanomedicine, Receptors, Chimeric Antigen, Cell Engineering, Immunotherapy, Adoptive. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nanomedicine is enabling in vivo chimeric antigen receptor (CAR) engineering of myeloid cells, but exposure and uptake do not establish a functional CAR-macrophage product. This oncology-focused narrative review organizes the evidence along five stages: anatomical access, cellular uptake, productive intracellular availability, CAR-protein expression, and antigen-dependent function. Cell identity and state are a cross-stage validation dimension rather than a sixth sequential event. Human tumor-associated macrophage atlases motivate measuring which cells express CAR, while an all-human acute myeloid leukemia screen challenges a universal CD47-centered phagocytosis hierarchy. Neither establishes a universally preferred solid-tumor macrophage state or checkpoint. We distinguish murine and human preclinical studies, peer-reviewed patient data, conference reports, sponsor disclosures, and trial registrations. Early in vivo myeloid programs support technical feasibility and repeat dosing, whereas clinically meaningful efficacy and state-selective engineering remain insufficiently established in the selected evidence. Protein-first assays, endpoint-matched models, quantitative cellular pharmacology, and product-specific potency testing offer a practical validation framework, with no validated universal thresholds. The literature cutoff is 31 August 2026. Clinical web information was checked through 12 August 2026.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanomedicineReceptors, Chimeric AntigenCell EngineeringImmunotherapy, AdoptiveTumor-Associated MacrophagesMacrophagesHumansAnimalsMiceNeoplasms

Stichwörter der Autor:innen

CAR macrophagein vivo cell engineeringlipid nanoparticlesmyeloid-targeted deliverynanomedicinetumor immunotherapy

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department and Institute of Urology, Hubei Provincial Clinical Research Center for Minimally Invasive Treatment of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan,…

ORCID-Profile: Haodong He, Zhihua Wang, Qidong Xia

Zitieren

APA

He, H., Sun, J., Xu, J., Abudureyimu, M., Yang, Y., Huang, Y., Wang, Z., & Xia, Q. (2026). Nanomedicine-Enabled in vivo CAR-Macrophage Engineering: Human Evidence, Translational Bottlenecks, and a Validation Framework. International Journal of Nanomedicine, Volume 21, 1-30. https://doi.org/10.2147/ijn.s653639

Vancouver

He H, Sun J, Xu J, Abudureyimu M, Yang Y, Huang Y, et al. Nanomedicine-Enabled in vivo CAR-Macrophage Engineering: Human Evidence, Translational Bottlenecks, and a Validation Framework. International Journal of Nanomedicine. 2026;Volume 21:1-30. doi:10.2147/ijn.s653639

BibTeX
@article{He2026,
  author = {He, Haodong and Sun, Jianxuan and Xu, Jingyu and Abudureyimu, Maimaiti and Yang, Yuxuan and Huang, Yifan and Wang, Zhihua and Xia, Qidong},
  title = {Nanomedicine-Enabled in vivo CAR-Macrophage Engineering: Human Evidence, Translational Bottlenecks, and a Validation Framework},
  journal = {International Journal of Nanomedicine},
  year = {2026},
  volume = {Volume 21},
  pages = {1--30},
  doi = {10.2147/ijn.s653639}
}
Kostenlos starten →